Nuclear Stock Face-Off: Is Oklo or Cameco the Better Buy Right Now?

Why It Matters

The race to secure low‑carbon, round‑the‑clock power for AI workloads makes nuclear fuel supply and advanced reactor technology pivotal, and investors must weigh stable uranium earnings against speculative reactor development risk.

Key Takeaways

• Cameco supplies 22 million lb uranium to India, $2.6 B contract.
• Cameco holds 49% of Westinghouse, linking to U.S. nuclear expansion.
• Oklo develops Aurora reactors, targeting 2027‑28 INL pilot.
• Oklo expects $350‑$450 M annual spend on reactor construction.
• Analysts favor Cameco over Oklo for immediate investment upside.

Pulse Analysis

The surge in artificial‑intelligence workloads has turned electricity into a strategic commodity, and nuclear power is re‑emerging as a low‑carbon solution that can run 24/7. Recent statements from the U.S. Energy Secretary and the Department of Energy’s loan guarantees signal a policy shift toward rebuilding decommissioned reactors and approving next‑generation designs. Major cloud providers—Microsoft, Amazon, Alphabet and Meta—are already signing long‑term power agreements with nuclear operators, accelerating capital inflows and creating a fertile environment for both uranium producers and reactor innovators.

Cameco (CCJ) stands at the center of this wave as the continent’s largest uranium miner. Its 22‑million‑pound uranium concentrate contract with India, valued at roughly $2.6 billion, locks in revenue through 2035, while a 49 % equity position in Westinghouse ties the company directly to the U.S. reactor build‑out. The firm’s exposure to the DOE loan program and its partnership with Brookfield Renewable give it a clear pathway to capture rising demand for fuel, supporting a stable dividend and modest valuation upside.

Oklo (OKLO) pursues a different angle, betting on modular, factory‑built reactors that could slash construction time and cost. Its Aurora Powerhouse, slated for a pilot at Idaho National Laboratory by late 2027, benefits from the DOE’s Reactor Pilot Program, which sidesteps the lengthy NRC commercial licensing track. However, the company projects $350‑$450 million in spend this year, and commercial deployment is not expected until the early 2030s, making cash‑flow risk a key consideration. For investors seeking near‑term earnings, Cameco’s established market position currently outweighs Oklo’s speculative upside.